If you and your provider decide to stop semaglutide, it is often recommended to gradually reduce the dose rather than stopping abruptly
Patients on semaglutide often experience less hunger, earlier fullness during meals, diminished cravings for high-calorie foods, increased energy for physical activity, and better-managed blood sugar levels
Contraindications include unstable mental health conditions, bipolar disorder, history of seizures, hyperthyroidism, unstable cardiovascular disease, and certain eye conditions
The dryness and loss of resilience that can appear as the weight comes off
Wegovy launched at about 17,345 per month for the lower strengths and up to 26,015 for higher-dose monthly treatment
Additionally, the reassuring safety findings further support the strong potential value of semaglutide in this population. Chronic kidney disease affects over 800 million people worldwide and is particularly prevalent among individuals with type 2 diabetes.2 Chronic kidney disease poses a significant risk of kidney failure, cardiovascular events and death,3 highlighting the critical need for research into its prevention and treatment
